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A microfluidic device has been developed to maintain viable heart tissue samples in a biomimetic 
microenvironment. This device allows rat or human heart tissue to be studied under pseudo in vivo 
conditions. Effluent levels of lactate dehydrogenase and hydrogen peroxide were used as markers of 
damaged tissue in combination with in situ electrochemical measurement of the release of reactive oxygen 
species (ROS). The parameters for perfusion were optimized to maintain biopsies of rat right ventricular or 
human right atrial tissue viable for up to 5 and 3.5 hours, respectively. Electrochemical assessment of the 
oxidation current of total ROS, employing cyclic voltammetry, gave results in real-time that were in good 
agreement to biochemical assessment using conventional, off-chip, commercial assays. This proof-of-
principle, integrated microfluidic device, may be exploited in providing a platform technology for future 
cardiac research, offering an alternative approach for investigating heart pathophysiology and facilitating 
the development of new therapeutic strategies. 
 
Introduction 
Studies of cardiac physiology and biochemistry have traditionally used in vitro perfusion systems such as 
the Langendorff retrograde perfusion.1,2 This model has been widely used for a diverse range of studies of 
the heart, including molecular and cellular alterations, as well as evaluating therapeutic interventions.  
The main alternative approaches for studying the pathophysiology of heart diseases are based on cell or 
tissue culture. However, the concern for all in vitro cell manipulation studies is that the cells behave 
differently in culture flasks,3 as the microenvironment experienced in vitro is clearly different from those 
in vivo. In addition, there is a further complication with adult cardiomyocytes as these can only be 
maintained as primary cell cultures, not immortal cell lines. Tissues and organs have complex three-
dimensional systems in situ, including a complex network of extra-cellular matrix, e.g. elastin, laminin, 
collagen and fibronectin. In addition, cells inhabit a closely packed spatio-temporal environment where 
any cell is always communicating and interacting with multiple other cell types, responding to local 
concentrations of a plethora of molecules, such as cytokines, enzymes and nutrients. Accordingly in an in 
vitro cell culture environment, many, if not all of these signals are missing. 
Microfluidics offers an approach that can circumvent many of the limitations of in vitro cell culture 
methodology. For example, by continuously supplying enriched media to heart tissue biopsies in vitro, 
whilst removing waste products and gases produced by cellular processes.4,5 Several groups have 
developed microfluidic devices for studying cardiomyocyte functions, with Li and Li being the first, 
investigating cell contraction.6 A single cardiomyocyte was retained within a V-shaped structure of the 
chip. Analysis of intracellular [Ca2+] following ionomycin stimulation was measured using the calcium-
sensitive dye, Fluo-4 AM ester. Subsequently, Li et al. developed a microfluidic chip with improved cell 
retention properties and used this to monitor calcium mobilization in single cardiomyocytes, in real-time, 
as a part of a drug screening application.7 Cheng et al. developed a multi-functional microfluidic platform 
with a microelectrode array to stimulate the cell and monitor lactate release by electrochemical (EC) 
probes.8 This analysis was used in conjunction with in situ microscopy and fluorescence detection of 
extracellular pH and cellular Ca2+ concentrations during cell contraction. However tissue, with its highly 
complex structures, presents a greater technological challenge in terms of maintaining essential supplies of 
oxygen and nutrients, whilst removing waste products. The benefits of studying a more holistic 
representation of the complex cell–cell and cell–stroma interactions are a greater relevance for 
physiological and clinical studies. 
Reactive oxygen species (ROS) play a major role in ischemia–reperfusion injury, ageing, 
neurodegenerative disorders and many other diseases.9,10 ROS can cause the oxidation of membrane 
phospholipids, DNA and proteins, subsequently impairing mitochondrial function. ROS can be measured 
by various means, such as chemiluminescence,11,12 fluorescence,13,14 infrared15 and electron spin resonance 
spectroscopy.16 Electrochemical methods, however, provide a direct means of analysing the concentration 
of free radicals in solution at the specific site where the sensing electrode is positioned, with minimal 
disturbance to the sample under investigation.17 Fast cyclic voltammetry has been carried out previously to 
capture the transient signals of extracellular nitric oxide or nitric oxide synthase (NOS) in brain slices.18,19 
Recently, triple potential-step chronoamperometry has been developed to measure simultaneously ROS 
and reactive nitrogen species (RNS).20 
Several groups have reported electrochemical sensors integrated with microfluidic devices to determine 
changes in ROS. A microfabricated Pt electrode was platinised to increase electrochemical sensitivity and 
used to detect ROS and RNS released from macrophage cells following continuous microinjection of a 
calcium ionophore.21 Electrochemical measurement has also been used to detect lactate released from heart 
cells7 and in saliva.22 Hitherto, electrochemical monitoring of ROS during perfusion of viable heart tissue 
biopsies has not been reported. 
Here, a microfluidic chip based perfusion system has been designed and optimised to maintain viable and 
functioning heart tissue samples. Analysis of tissue was performed on-chip by electrochemical 
measurements and verified off-chip by biochemical methods, as a route towards developing the next 
generation of user-friendly devices to maintain and analyse tissue to address clinically relevant issues. 
Experimental 
Experimental models 
All procedures conform to the UK Animals (Scientific Procedures) Act 1986. Wistar rats (B&K Universal 
Ltd., Grimston, UK) were housed under a 12:12 hour light–dark cycle and provided with food and water 
ad libitum. Animals were anaesthetized via intraperitoneal injection of 0.5 mL 100 g−1 sodium thiopentone 
(25 mg mL−1, Link Pharmaceuticals Ltd., West Sussex, UK). In brief, hearts were rapidly excised and the 
aorta was cannulated. A piece of right ventricular tissue (approximately 2 × 4 × 4 mm3) was taken and 
placed directly into the chamber of the perfusion device filled with buffer. At the end of the experiment, 
the wet weight of the heart tissue sample was recorded.  
Human heart tissue biopsies were supplied by Mr S. Griffin (Consultant Cardiothoracic Surgeon). Ethics 
and Hospital Trust approvals were obtained from Hull and East Yorkshire Local Research Ethics 
Committee (07/H1304/105) and Hull and East Yorkshire NHS Trust (R0568), respectively. Samples were 
taken from patients undergoing coronary artery bypass surgery (CABG). Heart biopsies were immersed in 
freshly prepared cardioplegic solution at 4 °C (Martindale Pharmaceuticals, UK), transported to the 
laboratory and mounted in the perfusion chamber within 60 minutes. 
Fabrication of microfluidic perfusion device 
A microfluidic perfusion chamber with a capacity of 400 µL was constructed from polydimethylsiloxane 
(PDMS) (Dow Corning, USA) and a polystyrene Petri dish (35 mm in diameter) (Fig. 1). Briefly, the 
chamber was moulded around the diamond-shaped end of a 1 mL syringe barrel that was attached to a 
silicon wafer using an instant adhesive (Henkel Loctite Adhesives Ltd., UK). Mixed and degassed PDMS 
monomer and initiator (w/w, 10 : 1) were poured over the syringe end and cured at 75 °C for two hours to 
form a mould. The PDMS chamber was stripped off the template and five holes (1–3 mm in diameter) 
were punched to allow for the inlet, and outlet Teflon™ tubings (1.0 mm ID × 1.6 mm OD, VWR Int. 
Ltd.), and electrodes. The PDMS was bonded with the Petri dish after oxygen plasma treatment at 350 V, 
20 mA, PO2 8 mbar for 50 s (SPEEDIVAC, Model 12E6/1405 Edwards High Vacuum Ltd., UK). This 
device provided a 7 mm chamber at its centre into which a heart biopsy was placed and positioned on a 
37 °C hotplate (WIS1, World Precision Instruments, UK). Both the inlet and outlet were connected to 
peristaltic pumps at a flow rate of 120 µL min−1, and the heart tissue was electrically stimulated via two 
platinum wire electrodes anchored in the chamber lid using a programmable, square wave, function 
generator (TG1010A, Thurlby Thandar Instruments Ltd., UK).  
 
 
Fig. 1 Schematics of the experimental setup (A and B): stimulation electrodes (a and b); working, 
reference and counter electrodes (c–e); tissue in chamber with Krebs–Henseleit buffer (supplemented 
with 5 mM glucose, 100 Units mL−1 penicillin and 100 µg mL−1 streptomycin, f); tissue holder (PDMS, 
g). Petri dish lid as the chamber cover and holder for electrodes and tubes (h). Polystyrene Petri dish (i). 
Photograph of the device with tissue (without the chamber lid) (C). 
 
Experimental protocols 
Prior to each experiment, the microfluidic system was sterilised with 70% (v/v) ethanol/water by perfusion 
at 120 µL min−1 and rinsed with sterilised double distilled water for 10 minutes, respectively. The 
microfluidic device was then primed with Krebs–Henseleit buffer (KH, 118 mM NaCl, 25 mM NaHCO3, 
4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgCl2 and 2.5 mM CaCl2) for 15 minutes. In this paper KHG 
represents KH buffer plus 5 mM glucose. The addition of 100 Unit mL−1 penicillin and 0.1 mg mL−1 
streptomycin (final concentration) to KHG buffer formed KHGB. All constituents were purchased from 
Sigma-Aldrich (UK) in the highest purity grade commercially available and used without further 
purification. Buffers were filtered using a 0.22 µm syringe filter (Millipore Corporation, USA) and 
oxygenated with 95% O2-5% CO2 continuously at 37 °C.  
Right ventricular tissue from rat or right atrial tissue biopsies from patients were perfused with KHGB for 
up to 5 hours followed by 30 minutes to one hour with 2% (v/v) Triton X100 (BDH, England) in KHGB. 
Triton X100 is a non-ionic surfactant able to solubilise phospholipid membranes,23 releasing the 
intracellular enzymes. In some experiments, 95% N2-5% CO2 saturated KHGB was used as an alternative 
method of inducing damage. 
Assessment of tissue functions 
1 Tissue viability. Viability was evaluated using calcein–acetoxymethyl ester (Calcein AM; Invitrogen, 
UK) and propidium iodide (PI; Sigma-Aldrich, UK). Calcein AM is a modified carboxylic acid containing 
an additional ester group that permits entry into cells. The ester is hydrolysed within viable cells altering 
hydrophobicity; the resulting carboxylate is both fluorescent and membrane impermeable. Conversely, PI 
only enters cells when the plasma membrane is disrupted where it intercalates with the double-stranded 
DNA and fluoresces, thus providing a measure of dead or dying cells. Following perfusion for various time 
periods, cardiac tissue sections were incubated with 50 µL of 10 µM calcein AM (λex = 494 nm and λem = 
517 nm) in phosphate buffered saline (PBS, pH 7.4) for 1 hour. The tissue was then washed with PBS and 
incubated with 50 µL of 3.75 mM PI (λex = 536 nm and λem = 617 nm) in PBS for 10 minutes. After a final 
wash with PBS, the cardiac tissue section was examined under a laser-scanning inverted confocal 
microscope (Nikon Eclipse TE2000-E).  
2 Lactate dehydrogenase measurement. Cell damage was determined via release of lactate dehydrogenase 
(LDH),24 using a commercial colorimetric assay (Cytotoxicity Detection KitPlus, Roche, UK). Effluent 
samples were collected for 2 min (approximately 240 µL in total) at 5 min intervals during perfusion from 
the outlet tube (see Fig. 1(A)). To measure LDH, samples (50 µL) were incubated with 50 µL of reaction 
mixture containing diaphorase/NAD+, iodotetrazolium chloride and sodium lactate for 30 min at room 
temperature in 96-well plates. The reaction was terminated by adding 50 µL of stop solution (1 M HCl) per 
well, and absorbance measured at 492 nm using a microplate reader (BioTek Instruments, Inc., USA). All 
samples were assayed in triplicate.  
3 Detection of H2O2. The concentration of H2O2 in the effluent was determined using a commercial 
Amplex Red Hydrogen Peroxide assay kit (Invitrogen Molecular Probes, UK). A standard curve ranging 
from 0 to 5 µM H2O2 was generated for each experiment. Samples (50 µL) were incubated with 50 µL of 
reaction mixture containing 100 µM Amplex Red reagent and 0.2 U mL−1 horseradish peroxidase (EC. 
1.11.1.7, one unit of enzyme will form 1.0 mg purpurogallin from pyrogallol in 20 seconds at pH 6.0 and 
20 °C) for 30 minutes at room temperature. Absorbance at 562 nm was measured using a microplate reader 
(BioTek Instruments Inc.). All results were corrected for background absorbance and expressed as the 
average of duplicate samples.  
4 Electrochemical monitoring of the total ROS. Electrochemical measurements were performed with the 
three-electrode system integrated onto the perfusion chip by a Palmsens potentiostat (PalmSens 
Instruments, Netherlands). This in-house produced system comprised one Pt disk electrode (250 µm in 
diameter) sealed in a glass tube (3 mm OD) which served as a working electrode (WE), a Pt wire as a 
counter electrode and Ag wire with a layer of AgCl operating as a reference electrode. Note that the saline 
buffer is sufficient to ensure that this reference maintains a constant potential. The AgCl layer was 
electrochemically coated by placing Ag wire in 100 mM NaCl solution and holding the potential at 0.45 V 
vs. Ag/AgCl (3 M NaCl) for 10 min until the oxidation current tailed to a residual. Potentials are reported 
versus this reference electrode unless otherwise stated. Prior to use, the working electrode was polished 
with 0.3 µm and 0.1 µm alumina slurry on polishing pads (Kemet International Ltd., Kent, UK), 
respectively and then successively cleaned in 10% (v/v) HNO3 and water in an ultrasonic bath. During 
tests, refreshing of the electrode surface was carried out by wiping the WE on a polishing cloth and rinsing 
with water. During in situ measurements, cleaning of the WE was carried out by electrochemical methods, 
such as differential pulse voltammetry (DPV) or cyclic voltammetry. During perfusion, cyclic voltammetry 
was conducted between −0.8 V and 1.0 V at a scan rate of 0.1 V s−1 and followed by a square wave 
voltammetry (SWV) scan from −0.55 V to 1.0 V with a frequency of 25 Hz, amplitude of 25 mV and a 
step of 5 mV. The first scan of cyclic voltammetry data was used for “non-polishing-mode” analysis while 
the second scan was used when polishing was undertaken, due to the enhanced sharpness of the feature in 
the second cycle. The electrochemical measurement was carried out when the stimulation pulse (ES) was 
switched off to obviate the deterioration in voltammograms.  
Results and discussion 
Perfusion system and viability assessment of tissue 
1 Establishment of an optimal perfusion system. The dimensions of the tissue samples were optimised so 
that sufficient oxygen was supplied to the heart tissue sample. Samples with dimensions of approximately 
4 × 2.5 × 2 mm3 were evenly labelled with calcein AM with little PI staining after perfusion for 5 hours 
(Fig. 2(A)). Larger heart tissue biopsies had a greater distance for oxygen and nutrient permeation from the 
edge to the core of the tissue sample; and thus the central region was strongly stained with PI but with a 
reduced calcein signal (Fig. 2(B)). Flow rates <100 µL min−1 meant that the collection of sufficiently sized 
aliquots took too long for repeated analysis, whereas flow rates ≥200 µL min−1 disturb the tissue and 
stimulation probes preventing reproducible assessment; see later and ESI† for EC optimisation. A flow rate 
of 120 µL min−1 was established as the standard flow rate for all subsequent experiments.  
 
 
Fig. 2 Representative confocal microscopy images of cardiac tissue sections treated with calcein AM 
(green fluorescence) and PI (red fluorescence) following 5 h incubation and an hour treatment with 2% 
(v/v) Triton X100. Tissue size in (A) ∼4 × 2.5 × 2 mm3; (B) ∼5 × 3.5 × 2 mm3. A 10× objective lens 
was used. The images were 400–500 µm from the bottom surface of the tissues. 
 
2 Establishment of on-chip electrical stimulation parameters. The heart tissue in the current study was 
stimulated electrically to mimic the in vivo situation. It was found that the excitation threshold for rat 
tissue to start beating and be maintained for at least 1 min was 1.0 V cm−1 at 2 Hz. Normally, the 
stimulation regime using square monophasic pulses, for a whole rat heart, occurs for a duration of 5 ms at a 
frequency of 5 Hz and amplitude of 1.5–2 V;25 or for approximately 3 ms at a frequency between 0.5 and 1 
Hz with a field strength of 5–6 V cm−1 for single rat ventricular cardiomyocytes.26,27 For rat tissue samples 
of the sizes described in Fig. 2 stimulation started at 0.8 V cm−1 and 2 Hz and the electric field was 
incrementally increased until all or part of the tissue commenced beating. At 1 V cm−1 the beating was 
observed to last more than 1 min. Bubbles due to solvent breakdown formed when the electrical field was 
≥12 V cm−1. A standardized frequency of 1.5 Hz with an electric field of 3–4 V cm−1 was chosen in order 
to obtain prolonged heart beating.  
The contractile function of tissue in the perfusion device became more pronounced, and generally lasted 
for longer periods of time when the calcium concentration in the KH buffer was increased from 1.25 to 2.5 
mM. The latter concentration was used as standard for all subsequent experiments. 
The optimized conditions (3–4 V cm−1, 1.5 Hz, 2.5 mM calcium chloride) maintained the heart tissue with 
regular contractions for up to 5 hours. Contraction of the electrically excited heart tissue sample was 
observed via a microscope camera (Veho, UK) during the perfusion of the majority of rat tissue biopsies, 
but only about 40% of human tissue samples showed this trend. The key determinant of damage was LDH 
release, measured in effluent samples and following incubation of the tissue with Triton X100 at the end of 
the perfusion period in the device. An alternative method of inducing injury was through perfusion with 
media containing 95% N2-5% CO2. It was observed that rat tissue ceased functioning within 10 min after 
incubation in KHG buffer saturated with this gas, associated with a marked increase in LDH release, 
similar to that observed after incubation with Triton X100 (Fig. 3). 
 
 
 
Fig. 3 LDH level in rat (A) or human (B) tissue. Tissues were perfused with oxygenated KHGB until 
300 min in (A), and 200 min in (B), followed by 2% (v/v) Triton X100 in KHGB. Stimulation pulse, 4 
V cm−1; 1.5 Hz. The LDH concentration was calculated in U mL−1 in (A) and subsequently standardised 
against the wet weight of human tissue (B). (Representation of three and eleven experiments in (A) and 
(B), respectively.) 
 
3 Viability in perfusion device as assessed by LDH release. Biopsies from right ventricular rat tissue were 
maintained in a viable state for at least 5 hours (Fig. 3A), whereas for human right atrial tissues, a period of 
3.5 hours was the maximum tested (Fig. 3B). LDH activities were high initially in every experiment, most 
likely due to damage caused when samples were taken and transported to the microdevice. Following this 
initial peak, the LDH levels remained at low levels, suggesting a recovery from the acute injury due to 
sufficient supplies of nutrients, oxygen and appropriate electrical stimulation in the flow perfusion 
chamber. When oxygen was removed from the buffer, electrical stimulation was stopped, or the biopsy 
was treated with Triton X100, the LDH levels showed a sharp increase within 10–15 minutes, verifying the 
viability of tissue prior to induction of damage.  
The current work here is distinct from tissue engineering constructs in microfluidic systems, which 
generate new tissues to restore, maintain, or enhance tissue function. The methodology described here 
allows direct experimentation on primary clinical samples under in vivo conditions. Similar work has been 
demonstrated by our group using liver tissue28 and colorectal tumour biopsies,29 both of which were kept 
viable for over 70 hours in the microfluidic environment. The liver tissue produced albumin and urea 
during perfusion, whereas the colorectal tissue produced vascular endothelial growth factor in response to 
hypoxia, demonstrating that both cell types were functional and responded in a similar manner to tissue in 
vivo. 
ROS monitoring by electrochemistry 
ROS or NOS can be measured by various kinds of chemical means.11–16 Electrochemical measurement has 
distinct advantages in terms of sensitivity and speed for real-time assessment, in situ. Previously H2O2 has 
been reported to be released at a rate of 50 nmol g−1 min−1 two minutes after an ischaemia/reperfusion 
episode.30 Following previous work in our laboratory regarding the development of a hydrogen peroxide 
biosensor, preliminary studies indicated that this enzyme-modified electrode could be employed to 
measure H2O2 using the current methodology.31 Given that the half-life of H2O2 is longer than that of the 
other ROS and NOS, we chose to employ direct H2O2 oxidation at Pt electrodes as the validation of part of 
ROS.  
1 Species confirmation and identification of the monitoring window. Details regarding the amperometric 
monitoring of ROS are given in ESI 1†; in summary it was observed that potentials of +0.72 V vs. 
Ag/AgCl allowed for the oxidative detection of ROS.21,32  
2 Control tests. Monitoring the current change continuously in the perfusion system is a challenge because 
many parameters can cause interference with the electrochemical measurements. The cleanliness of the 
WE, the presence or absence of oxygen and nitrogen in different stages of the perfusion, Triton X100 and 
the stimulation for maintenance of the heart “beat” were the main interfering parameters.  
Two modes of control test for EC measurement were studied: non-polishing and polishing of the electrode 
in the relevant buffers. In the first mode, the WE was scanned initially in KH solution from −0.8 V to 1.0 
V until a stable response was observed; the electrode remained in place within the chamber during 
perfusion without cleaning prior to voltammetric measurement. In the second control the WE was polished 
and rinsed with water before each measurement; Fig. 4 illustrates these results. It was found that the 
“on/off” stimulation pulse caused fluctuations in the background current measured using cyclic 
voltammetry or SWV. When no stimulation pulse was applied, the baseline was relatively noise-free and 
stable with a low standard deviation (Fig. 4a, and ESI 2, Table S1†). 
 
 
 
Fig. 4 Control tests in different buffer solutions using polished electrodes. Between 0–30 min and 90–
125 min, no stimulation pulse; 40–80 min, stimulation pulse on while not conducting EC measurement. 
IO at 0.72 V in cyclic voltammetry in KHGB buffer with Triton X100 from the 90th min (a, solid circle), 
in KHG with 95% N2-5% CO2 from the 90th min (b, empty star) and in KH (c, square-cross). IO at 0.3 V 
in SWV with 95% N2-5% CO2 from 90 min, in KHG (d, solid star), and KHGB (e, solid triangle). Flow 
rate: 120 µL min−1 for all perfusions. (Representative of three independent experiments.) 
 
Higher variances of oxidation current (IO) were observed when electrical stimulation was applied, as 
expected (region 40–80 min in Fig 4). Glucose and antibiotics were not responsible for this because further 
tests in KH and KHG buffers suggested a similar fluctuation within this period (Fig. 4b and c). When 
electrical stimulation is applied ionic species will redistribute around the pulse probes to form electrical 
double layers, which may alter the background current of a voltammetric measurement each time this 
stimulation is turned on. In order to mitigate this effect EC measurement was delayed for 5 seconds after 
the pulse ceased to ensure sufficient time for the double layer around the electrode to resettle in the 
presence of freshly flowing buffer. 
3 Study of induction of injury and in situ EC measurement. In Triton X100–KHGB with no electrical 
simulation (90 to 125 min), the background current IO at 0.72 V in cyclic voltammetry fluctuated by up to 
±10% compared with those between 40 and 80 min without Triton X100; whilst in 95% N2-5% CO2–
KHGB, IO increased less than 6% on average (Fig. 4). The surfactant was reported to enhance efficiently 
the electron transfer between solution and electrode surface due to its strong adsorption on the hydrophobic 
electrode surface.33 Since the use of Triton X100 in tissue-free buffer caused an increased signal of up to 
10%, the tissue would be considered alive before the assault only when the current measured in EC 
increased by more than 15%.  
In order to achieve in situ EC measurement, a non-polished electrode was first used. The baseline was 
found to be smooth and stable when there were no electrical stimulation periods but suffered poor 
reproducibility and a decreasing baseline when stimulation pulses were switched on. The average IO 
decreased more than 20% with addition of Triton X100, and the relative standard deviation was 12% on 
average. The WE also became easily contaminated during voltammetry scans. This was confirmed by 
using a Pt disk electrode in N,N,N′,N′-tetramethyl-p-phenylenediamine solutions (TMPD, Sigma) before 
and after cyclic voltammetry scans in KHGB and KH (ESI 3, Fig. S2†). Distorted voltammograms were 
observed in the range of 0.05 V to −0.02 V in the TMPD solution after scans in KH buffers. However, 
when operating in the non-polishing mode, it was necessary to minimise disturbances of the device once 
established, hence a method for cleaning the electrode in situ by electrochemistry was designed. DPV and 
cyclic voltammetry, which scan to high potentials (from −0.5 V to 1.5 V with the ES-on), were 
demonstrated to clean the WE effectively in situ, when fouling was observed by increased reduction 
currents around 0.8 V in cyclic voltammograms. 
In order to increase the sensitivity of the EC measurement and shorten the record time, thus limiting any 
potential disruption of the perfusion, measurement of ROS by SWV was also studied. Generally, the 
average IO at 0.25 V in SWV was smaller than that in cyclic voltammetry (Fig. 4 (d, KHG) and (e, 
KHGB)). This lower current at 0.25 V in KHGB is due to the presence of antibiotics ((d) in Fig. S1A, 
inset†), which may induce electrode surface blocking after the SWV scan. This can be found in 90–125 
min area when 95% N2-5% CO2 took the place of O2 and electrical stimulation was off; the standard 
deviation was better than in cyclic voltammetry, whilst the variance of IO after N2 treatment was ±20%, 
higher than in cyclic voltammetry. 
4 ROS results compared with LDH and H2O2 assays. Fig. 5A shows the results of LDH and in situ EC 
measurement of ROS in real time. The electrode was cleaned by the EC method described above. The 
profile of LDH release (measured off-chip) and EC agreed well, with relatively high levels in the early 
stage of the perfusion, this then decreased and remained low until a sharp increase was induced with the 
addition of Triton X100. The electrode was cleaned by DPV with scans from −0.8 V to 1.5 V before the 
25th, 55th, 140th and 190th min, when the WE was contaminated (an early sign was increased cathodic 
current around 0.8 V in cyclic voltammetry). The decrease of signal at the 55th and 190th min accordingly 
is likely to be due to this action. It was noted that the length of time between obtaining the biopsy and 
placing this in the chamber was correlated with electrode contamination, i.e. when placed in the device 
within 5 minutes, little electrode contamination was observed; unfortunately the human tissue had to be 
transported from the hospital site and took up to 60 min from biopsy to device.  
  
Fig. 5 Comparison of LDH, H2O2 and total ROS by EC in human sample perfusion. (A) Release of 
LDH (blue circles) and ROS by cyclic voltammetry (filled circles). In situ electrode cleaning by DPV, 
scanning from −0.5 V to 1.5 V before the 25th, 55th, 140th and 190th min. (B) LDH (blue circles), H2O2 
(red circles) from Amplex Red assay and ROS by cyclic voltammetry (filled circles) with perfusion. The 
electrode was polished before each scan. Perfusion with 95% O2-5% CO2–KHGB with ES until the 200th 
min then electrical stimulation was turned off and the sample was incubated with Triton X100-KHGB in 
(A), or 95% N2-5% CO2–KHGB in (B). Stimulation pulse: 4 V cm−1, 1.5 Hz; EC measurements were 
carried out with the pulse off. (Representative of three independent experiments.) 
 
Fig. 5B shows the comparison of LDH, H2O2 release with total ROS by electrochemical measurement in a 
polishing mode. During perfusion, cyclic voltammetry and SWV measurements took 1.5 min, while it took 
2 min to collect sufficient effluents for H2O2 assay and another 2 min for LDH analysis. Taking these small 
differences into account, the LDH release matched the H2O2 levels, except between 100 and 160 min 
where there was a raised level of H2O2, with only minor fluctuations in LDH. However, the IO in cyclic 
voltammetry and SWV agreed well with the H2O2 assay results in the main, especially at 130 min where 
LDH did not detect damage (see ESI 4, Fig. S3† for SWV results). 
The [H2O2] at 220 min was determined to be 1.18 µM from the off-chip biochemical assay and 3 µM by 
electrochemical means after calibration with standard H2O2 in the flow system (ESI 5, Fig. S4†), indicating 
that the total ROS included H2O2 plus additional ROS. As stated above it has been reported that H2O2 was 
released from rat heart tissue at a rate of 50 nmol g−1 min−1 two minutes after an ischaemia/reperfusion 
incident.30 Given the chamber size of the device used in this work was 0.4 mL, with a tissue weight of 0.03 
g, these parameters would give an H2O2 concentration of approximately 3.75 µM min−1 for our tissue. In 
contrast, a release rate of 3 × 10−18 mol s−1 per cell for H2O2 by human neutrophils has been reported.34 
Assuming an average rat or human cardiomyocyte from the ventricle has a volume 30 000 µm3 (this varies 
considerably with age and sex)35 and tissue biopsy dimensions of 2 × 4 × 4 mm3 would give a calculation 
of 0.48 µM min−1 for H2O2. These values do not take into account differences in cell type, nature of the 
cell sample, i.e. in the tissue a restricted number of cells are initially exposed to the Triton X100, or 
stimulation method, however the production rates are of a similar scale. Interestingly the H2O2 release 
occurred prior to LDH, indicating that oxidative damage preceded membrane damage and LDH release. 
It was found that 95% N2-5% CO2 was a good alternative to Triton X100 for inducing cell damage, due to 
the gas having less effect on the background current in cyclic voltammetry. It induced a similar release of 
LDH 10 min earlier than Triton X100 did (the 240th min in Fig. 3B and the 230th min in Fig. 5B). 
However, the LDH rise was smaller than that caused by the detergent treatment. This is most likely due to 
Triton acting directly on the cell membranes rather than an indirect effect associated with a lack of oxygen. 
It is hypothesised that longer periods of perfusion with the 95% N2-5% CO2 media would result in a 
similar level of cell rupture and LDH release. 
Conclusions 
A microfluidic device has been developed for heart tissue perfusion with real-time electrochemical 
monitoring of ROS release. Having optimized the perfusion and stimulation conditions, it is possible to 
maintain viable tissue biopsies from rat and human tissue for up to 300 min, a typical time frame for 
current in vitro models. In situ, real-time electrochemical measurement of total ROS was achieved, 
matching the release of LDH determined off-chip. Both cyclic voltammetry and square wave voltammetry 
have been utilised to monitor ROS levels and the concentrations detected have been verified by 
biochemical assay of H2O2. In summary, this study describes a novel method to monitor continuously the 
change of ROS and other factors in heart tissue biopsies, and will facilitate investigations of normal and 
pathological cardiac functions ex vivo, whilst mimicking the in vivo environment.  
Acknowledgements 
Thanks are given to Mr Steven Griffin (Castle Hill Hospital) for providing the human cardiac biopsies. 
This study was supported by Heart Research UK (RG2538/07/10) and BBSRC (BB/E002722/1).  
References 
References 
1 H. Zimmer, News Physiol. Sci., 1998, 13, 203–210. 
2 A. Akki, K. Smith and A.-M. L. Seymour, Mol. Cell. Biochem., 2008, 311, 215–224. 
3 S. Zhang, Nat. Biotechnol., 2004, 22, 151–152. 
4 J. H. Yeon and J. Park, Biochip J., 2007, 1, 17–27. 
5 P. J. Hung, P. J. Lee, P. Sabounchi, R. Lin and L. P. Lee, Biotechnol. Bioeng., 2005, 89, 1–8. 
6 X. Li and P. C. H. Li, Anal. Chem., 2005, 77, 4315–4322. 
7 X. Li, J. Huang, G. F. Tibbits and P. C. H. Li, Electrophoresis, 2007, 28, 4723–4733. 
8 W. Cheng, N. Klauke, H. Sedgwick, G. L. Smith and J. M. Cooper, Lab Chip, 2006, 6, 1424–1431. 
9 E. J. Lesnefsky, S. Moghaddas, B. Tangler, J. Kerner and C. L. Hoppel, J. Mol. Cell. Cardiol., 2001, 33, 
1065–1089. 
10 W. Drōge, Physiol. Rev., 2002, 82, 47–95. 
11 C.Lu,G.Song andJ. Lin,TrAC,TrendsAnal.Chem., 2006, 25, 985–995. 
12 R. Mahfouz, R. Sharma, J. Lachner, N. Aziz and A. Agarwal, Fertil. Steril., 2009, 92, 819–827. 
13 J. R. Henderson, D. A. Fulton, C. J. McNeil and P. Manning, Biosens. Bioelectron., 2009, 24, 3608–
3614. 
14 H. Li, Q. Li, X. Wang, K. Xu, Z. Chen, X. Gong, X. Liu, L. Tong and B. Tang, Anal. Chem., 2009, 81, 
2193–2198. 
15 A. Chandrasekaran and M. Packirisamy, J. Biomed. Opt., 2009, 14(5), 054050. 
16 N. Weissmann, N. Kuzkaya, B. Fuchs, V. Tiyerili, R. U. Schäfer, H. Schütte, H. A. Ghofrani, R. T. 
Schermuly, C. Schudt, A. Sydykov, B. Egemnazarow, W. Seeger and F. Grimminger, Respir. Res., 2005, 
6, 86 . 
17 C. Amatore, S. Arbault, C. Bouton, K. Coffi, J. C. Drapier, H. Ghandour and Y. H. Tong, 
ChemBioChem, 2006, 7(4), 653–661. 
18 S. J. Starkey, A. L. Grant and R. M. Hagan, Br. J. Pharmacol., 2001, 134, 1084–1092. 
19 J. J. O’Connor and C. O’Neill, Sensors, 2008, 8, 5516–5534. 
20 C. Amatore, S. Arbault and A. Koh, Anal. Chem., 2010, 82(4), 1411–1419. 
21 C. Amatore, S. Arbault, Y. Chen, C. Crozatier and I. Tapsoba, Lab Chip, 2007, 7, 233–238. 
22 C. G. J. Schabmueller, D. Loppow, G. Piechotta, B. Schütze, J. Albers and R. Hintsche, Biosens. 
Bioelectron., 2006, 21, 1770–1776. 
23 P. S. C. Pret_e, S. V. P. Malheiros, N. C. Meirelles and E. de Paula, Biophys. Chem., 2002, 97, 1–5. 
24 A. J. Racher, D. Looby and J. B. Griffiths, Cytotechnology, 1990, 3, 301–307. 
25 M. L. Field, A. Azzawi, P. Styles, C. Henderson, A.-M. L. Seymour and G. K. Radda, Cell Calcium, 
1994, 16, 87–100. 
26 N. Klauke, G. Smith and J. Cooper, Lab Chip, 2007, 7, 731–739. 
27 N. Klauke, G. Smith and J. Cooper, Biophys. J., 2003, 85, 1766–1774. 
28 S. M. Hattersley, C. E. Dyer, J. Greenman and S. J. Haswell, Lab Chip, 2008, 8, 1842–1846. 
29 A. Webster, C. E. Dyer, S. J. Haswell and J. Greenman, Anal. Methods, 2010, 2, 1005–1007. 
30 J. Slezak, N. Tribulova, J. Pristacova, B. Uhrik, T. Thomas, N. Khaper, N. Kaul and P. K. Singalt, Am. 
J. Pathol., 1995, 147, 772–781. 
31 Y. Dou, S. Haswell, J. Greenman and J. Wadhawan, Electrochem. Commun., 2009, 11, 1976–1981. 
32 R. Kohen, J. Pharmacol. Toxicol. Methods, 1993, 29, 185–193. 
33 S. Zhang, K. Wu and S. Hu, Talanta, 2002, 58, 747–754. 
34 S. Shleev, J. Wettero, K. E. Magnusson and T. Ruzgas, Cell Biol. Int., 2008, 32, 1486–1496. 
35 S. E. Campbell, K. Rakusan and A. M. Gerdes, Basic Res. Cardiol., 1989, 84, 247–258. 
 
 
